Traws Pharma blue.png
Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor
30 sept. 2024 07h30 HE | Traws Pharma, Inc.
Ratutrelvir was well-tolerated for 10 days and achieved consistent plasma levels in the predicted therapeutic window, without the need for co-administration of ritonavir Phase 2a study...
Traws Pharma blue.png
Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors
20 sept. 2024 07h30 HE | Traws Pharma, Inc.
Experienced Life Sciences Executive Brings Strategic Expertise to Support Traws’ Further Transformation and Growth Director James J Marino Also to Step Down from Traws Board After a Decade of...
Traws Pharma blue.png
Traws Pharma, Inc. Announces Special Shareholders Meeting Results
17 sept. 2024 16h05 HE | Traws Pharma, Inc.
Three proposals, including a reverse stock split, were submitted and approved Traws Board subsequently approved a 1-for-25 reverse stock split Traws’ shares expected to begin trading on...
Traws Pharma blue.png
Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights
15 août 2024 07h00 HE | Traws Pharma, Inc.
Merger with Trawsfynydd Therapeutics, Inc (“Trawsfynydd”) and concurrent private placement of $14 million (cash runway to support planned operations through year end), with recently achieved clinical...
Traws Pharma blue.png
Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET
14 août 2024 16h30 HE | Traws Pharma, Inc.
NEWTOWN, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing oral small molecules for respiratory viral...
Traws Pharma blue.png
Traws Pharma’s ICAR Poster Highlights Potency of COVID-19 Candidate
23 mai 2024 08h00 HE | Traws Pharma, Inc.
Traws Pharma’s ICAR Poster Highlights Potency of COVID-19 Candidate
Traws Pharma blue.png
Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update
16 mai 2024 09h29 HE | Traws Pharma, Inc.
Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update
Traws Pharma blue.png
Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy
07 mai 2024 08h00 HE | Traws Pharma, Inc.
Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy
Onconova Logo BLUE.jpg
Traws Pharma Announces New Employee Inducement Grants
02 avr. 2024 07h15 HE | Onconova Therapeutics, Inc.
NEWTOWN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (Nasdaq: TRAW, “Traws”, the “Company”) today announced it has granted equity awards to new employees who joined Traws in...
Onconova Logo BLUE.jpg
Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company
02 avr. 2024 07h00 HE | Onconova Therapeutics, Inc.
Closing cash balance of approximately $28 million expected from concurrent private placement led by OrbiMed and Torrey PinesFunding expected to advance development of three potential...